J Korean Med Assoc.  2016 May;59(5):379-384. 10.5124/jkma.2016.59.5.379.

Recent advances in management of gout

• Song JS

• KMID: 2420637
• DOI: http://doi.org/10.5124/jkma.2016.59.5.379

Abstract

Gout, which is caused by the deposition of monosodium urate crystals in synovial fluid and other tissues, is the most common inflammatory rheumatic disease in men, at least in the Western world, and is increasing in prevalence worldwide. In addition to extremely painful recurrent acute and chronic arthritis, gout is associated with chronic kidney diseases and metabolic syndrome, including dyslipidemia, hypertension, hyperglycemia, and obesity. Thus it has an impact on morbidity and premature mortality. For the proper management of gout, definite diagnosis should come first. Management plans for the treatment of gout have to be designed to meet the requirements of each individual patient and to control both gout and its associated disorders. The goals of treatment for gout are fast pain relief and the prevention of future gout attacks and long-term complications, such as joint destruction and other comorbidities. In this article, recent advanced non-pharmacologic and pharmacologic management strategies for gout and hyperuricemia will be described.

Keyword

Gout; Uric acid; Hyperuricemia; Management

MeSH Terms

Arthritis
Comorbidity
Diagnosis
Dyslipidemias
Gout*
Humans
Hyperglycemia
Hypertension
Hyperuricemia
Joints
Male
Mortality, Premature
Obesity
Prevalence
Renal Insufficiency, Chronic
Rheumatic Diseases
Synovial Fluid
Uric Acid
Western World
Uric Acid

Reference

1. Choi HK, Mount DB, Reginato AM. American College of Physicians. American Physiological Society. Pathogenesis of gout. Ann Intern Med. 2005; 143:499–516.

2. Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, Song GG. Prevalence of the metabolic syndrome in patients with gout. J Korean Rheum Assoc. 2004; 11:349–357.

3. Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, Chung SH, Kim CG, hoe JY, Lee SW, Chung WT, Song GG. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci. 2005; 20:1029–1033.

4. Kuo CF, Yu KH, See LC, Chou IJ, Tseng WY, Chang HC, Shen YM, Luo SF. Elevated risk of mortality among gout patients: a comparison with the national population in Taiwan. Joint Bone Spine. 2011; 78:577–580.

5. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011; 63:3136–3141.

6. Son KM, Seo YI, Kim IJ, Bae YD, Jung YO, Cha MJ, Kim HA. Adherence to uric acid lowering agent of gouty patients. J Korean Rheum Assoc. 2010; 17:162–167.

7. Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Liote F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vaquez-Mellado J, Yarows SA, Taylor WJ. 2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015; 67:2557–2568.

8. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013; 72:826–830.

9. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R. American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012; 64:1431–1446.

10. Choi HJ, Lee YJ, Park JJ, Lee JC, Lee EY, Lee EB, Song YW. The effect of low dose aspirin on serum and urinary uric acid level in gouty arthritis patients. J Korean Rheum Assoc. 2006; 13:203–208.

11. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I;. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65:1312–1324.

12. Yamanaka H. Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011; 30:1018–1029.

13. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R. American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012; 64:1447–1461.

14. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004; 51:321–325.

15. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002; 47:356–360.

16. Jung JW, Song WJ, Kim YS, Joo KW, Lee KW, Kim SH, Park HW, Chang YS, Cho SH, Min KU, Kang HR. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant. 2011; 26:3567–3572.

17. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT. HLAB^*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005; 102:4134–4139.

18. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W. Strong association between HLA-B^*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009; 19:704–709.

19. Hautekeete ML, Henrion J, Naegels S, DeNeve A, Adler M, Deprez C, Devis G, Kloppel G. Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities. Liver. 1995; 15:25–29.

20. Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008; 31:643–665.

21. Perez-Ruiz F, Hernandez-Baldizon S, Herrero-Beites AM, Gonzalez-Gay MA. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout. Arthritis Care Res (Hoboken). 2010; 62:1299–1305.

22. Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011; 306:711–720.